Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026137 | 0.81 | HPGD (0.48) | HPGDAKR1C3SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL13246476 | 0.81 | MGLL (0.60) | HPGDAKR1C3SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL424321 | 0.78 | MGLL (0.59) | NOTUMMGLL | |
| SCHEMBL3023940 | 0.75 | MGLL (0.40) | HPGDSMN1; SMN2HTTKMT2AMGLL | |
| SCHEMBL5642333 | 0.74 | FAAH (0.48) | HPGDSMN1; SMN2LMNAHTTNOTUM | |
| SCHEMBL13246567 | 0.73 | HPGD (0.51) | HPGDSMN1; SMN2HTTNOTUMKMT2A | |
| SCHEMBL14548203 | 0.72 | LMNA (0.43) | HPGDAKR1C3ALDH1A1LMNAHTT | |
| SCHEMBL5642851 | 0.72 | FAAH (0.53) | HPGDSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL5643728 | 0.72 | PRMT5 (0.43) | SMN1; SMN2ALDH1A1LMNANOTUMKMT2A | |
| SCHEMBL5640593 | 0.72 | HSP90AA1 (0.43) | HPGDAKR1C3SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940838-B1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | HPGD 840/4885AKR1C3 2553/4885SMN1; SMN2 4402/4885 |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | HPGD 840/4885AKR1C3 2553/4885SMN1; SMN2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.